S&P 500   3,783.28 (-0.20%)
DOW   30,273.87 (-0.14%)
QQQ   281.98 (-0.05%)
AAPL   146.40 (+0.21%)
MSFT   249.20 (+0.13%)
META   138.98 (-0.93%)
GOOGL   101.43 (-0.21%)
AMZN   120.95 (-0.12%)
TSLA   240.81 (-3.46%)
NVDA   132.09 (+0.32%)
NIO   16.04 (-4.12%)
BABA   84.39 (+0.33%)
AMD   67.94 (+0.06%)
T   15.93 (-0.99%)
MU   54.73 (+1.43%)
CGC   3.07 (-2.23%)
F   12.51 (+1.21%)
GE   67.44 (-0.15%)
DIS   100.80 (-0.63%)
AMC   7.33 (-6.39%)
PYPL   93.83 (+1.12%)
PFE   44.12 (-0.76%)
NFLX   236.73 (-1.67%)
S&P 500   3,783.28 (-0.20%)
DOW   30,273.87 (-0.14%)
QQQ   281.98 (-0.05%)
AAPL   146.40 (+0.21%)
MSFT   249.20 (+0.13%)
META   138.98 (-0.93%)
GOOGL   101.43 (-0.21%)
AMZN   120.95 (-0.12%)
TSLA   240.81 (-3.46%)
NVDA   132.09 (+0.32%)
NIO   16.04 (-4.12%)
BABA   84.39 (+0.33%)
AMD   67.94 (+0.06%)
T   15.93 (-0.99%)
MU   54.73 (+1.43%)
CGC   3.07 (-2.23%)
F   12.51 (+1.21%)
GE   67.44 (-0.15%)
DIS   100.80 (-0.63%)
AMC   7.33 (-6.39%)
PYPL   93.83 (+1.12%)
PFE   44.12 (-0.76%)
NFLX   236.73 (-1.67%)
S&P 500   3,783.28 (-0.20%)
DOW   30,273.87 (-0.14%)
QQQ   281.98 (-0.05%)
AAPL   146.40 (+0.21%)
MSFT   249.20 (+0.13%)
META   138.98 (-0.93%)
GOOGL   101.43 (-0.21%)
AMZN   120.95 (-0.12%)
TSLA   240.81 (-3.46%)
NVDA   132.09 (+0.32%)
NIO   16.04 (-4.12%)
BABA   84.39 (+0.33%)
AMD   67.94 (+0.06%)
T   15.93 (-0.99%)
MU   54.73 (+1.43%)
CGC   3.07 (-2.23%)
F   12.51 (+1.21%)
GE   67.44 (-0.15%)
DIS   100.80 (-0.63%)
AMC   7.33 (-6.39%)
PYPL   93.83 (+1.12%)
PFE   44.12 (-0.76%)
NFLX   236.73 (-1.67%)
S&P 500   3,783.28 (-0.20%)
DOW   30,273.87 (-0.14%)
QQQ   281.98 (-0.05%)
AAPL   146.40 (+0.21%)
MSFT   249.20 (+0.13%)
META   138.98 (-0.93%)
GOOGL   101.43 (-0.21%)
AMZN   120.95 (-0.12%)
TSLA   240.81 (-3.46%)
NVDA   132.09 (+0.32%)
NIO   16.04 (-4.12%)
BABA   84.39 (+0.33%)
AMD   67.94 (+0.06%)
T   15.93 (-0.99%)
MU   54.73 (+1.43%)
CGC   3.07 (-2.23%)
F   12.51 (+1.21%)
GE   67.44 (-0.15%)
DIS   100.80 (-0.63%)
AMC   7.33 (-6.39%)
PYPL   93.83 (+1.12%)
PFE   44.12 (-0.76%)
NFLX   236.73 (-1.67%)
NYSE:RMD

ResMed - RMD Price Target & Analyst Ratings

$231.76
+3.03 (+1.32%)
(As of 10/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$227.78
$235.00
50-Day Range
$212.32
$243.58
52-Week Range
$189.40
$275.66
Volume
595,100 shs
Average Volume
560,782 shs
Market Capitalization
$33.94 billion
P/E Ratio
43.65
Dividend Yield
0.77%
Price Target
$266.40

ResMed Consensus Rating and Price Target (2022)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 9 Analyst Ratings

Consensus Analyst Price Target

$266.40
14.95% Upside
High Prediction$280.00
Average Prediction$266.40
Low Prediction$250.00
TypeCurrent
10/5/21 to 10/5/22
1 Month Ago
9/5/21 to 9/5/22
3 Months Ago
7/7/21 to 7/7/22
1 Year Ago
10/5/20 to 10/5/21
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
6 Buy rating(s)
5 Buy rating(s)
8 Buy rating(s)
4 Buy rating(s)
Hold
3 Hold rating(s)
4 Hold rating(s)
3 Hold rating(s)
5 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
3 Sell rating(s)
Consensus Price Target$266.40$266.40$260.67$241.50
Predicted Upside14.95% Upside11.68% Upside9.94% Upside0.50% Upside
Get ResMed Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for RMD and its competitors with MarketBeat's FREE daily newsletter.


RMD Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

RMD Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

ResMed Stock vs. The Competition

TypeResMedMedical CompaniesS&P 500
Consensus Rating Score
2.67
2.68
2.49
Consensus RatingModerate BuyBuyHold
Predicted Upside16.82% Upside1,094.46% Upside29.45% Upside
News Sentiment RatingNeutral News
Positive News
Neutral News
MarketBeat
Community Rating
Outperform Votes
386
52.73%
Underperform Votes
346
47.27%
Avg. Outperform Votes
166
66.67%
Avg. Underperform Votes
83
33.33%
Avg. Outperform Votes
852
68.38%
Avg. Underperform Votes
394
31.62%

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
9/8/2022Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy
8/12/2022JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOverweight ➝ Neutral
8/12/2022Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Craig Wong-Pan
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Sector Perform$246.00 ➝ $252.00+4.63%
4/5/2022Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$280.00+14.10%
1/30/2022The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy
1/28/2022Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Michael Polark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Target$300.00 ➝ $280.00+24.51%
1/24/2022Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeUnderperform ➝ Neutral$239.00 ➝ $250.00+6.31%
12/6/2021Macquarie
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Outperform
10/22/2021CLSA
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeUnderperform ➝ Outperform
8/9/2021Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Michael Matson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold
7/28/2021Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeUnderperform ➝ Hold$170.00 ➝ $240.00-9.17%
6/15/2021Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$240.00 ➝ $270.00+16.53%
11/2/2020UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$210.00+9.41%
10/30/2020Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Outperform
8/6/2020Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Sean Laaman
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Equal Weight
3/24/2020William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Margaret Kaczor
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy
11/22/2019KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageSector Weight ➝ Sector Weight
(Data available from 10/5/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












RMD Price Target - Frequently Asked Questions

What is ResMed's consensus rating and price target?

According to the issued ratings of 9 analysts in the last year, the consensus rating for ResMed stock is Moderate Buy based on the current 3 hold ratings and 6 buy ratings for RMD. The average twelve-month price prediction for ResMed is $266.40 with a high price target of $280.00 and a low price target of $250.00. Learn more on RMD's analyst rating history.

Do Wall Street analysts like ResMed more than its competitors?

Analysts like ResMed less than other Medical companies. The consensus rating for ResMed is Moderate Buy while the average consensus rating for medical companies is Buy. Learn more on how RMD compares to other companies.

Do MarketBeat users like ResMed more than its competitors?

MarketBeat users like ResMed less than other Medical companies. 52.73% of MarketBeat users gave ResMed an outperform vote while medical companies recieve an average of 66.67% outperform votes by MarketBeat users.

Is ResMed being upgraded or downgraded by Wall Street analysts?

Over the previous 90 days, ResMed's stock had 3 downgrades and 1 upgrade by analysts.

Does ResMed's stock price have much upside?

According to analysts, ResMed's stock has a predicted upside of 11.68% based on their 12-month price targets.

What analysts cover ResMed?

ResMed has been rated by Citigroup, JPMorgan Chase & Co., and Royal Bank of Canada in the past 90 days.


Stock Ratings Reports and Tools

This page (NYSE:RMD) was last updated on 10/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.